Group 1 - The announcement states that交银施罗德基金管理有限公司 has signed a sales agreement with 西部证券股份有限公司 to add it as a sales institution for its funds starting from August 22, 2025 [1] - The specific funds applicable under this agreement will be determined based on compliance with the fund contract and prospectus, with details on sales processes, types of business, and any fee discounts subject to the arrangements of the sales institution [1] - Investors can consult for more details through 西部证券's customer service or the official website of 交银施罗德基金 [1] Group 2 - The announcement is officially made by 交银施罗德基金管理有限公司 on August 22, 2025 [2] - The document also mentions the formation of a MACD golden cross signal, indicating positive trends in certain stocks [2]

Summary of Key Points Core Viewpoint - The company, Hunan Jiutian Pharmaceutical Co., Ltd., is changing the use of raised funds from a new drug research project to a new antibacterial peptide drug research project due to market environment changes and actual development needs [1][9]. Group 1: Fundraising Overview - The company raised a total of RMB 270 million through the issuance of convertible bonds, with a net amount of RMB 262.62 million transferred to a special account [1]. - As of June 30, 2025, the company has invested RMB 176.04 million in fundraising projects, leaving a remaining balance of RMB 98.09 million [2][3]. Group 2: Change in Fund Usage - The original project, which involved the development of improved new drugs, has seen an investment of RMB 19.69 million, with RMB 98.09 million remaining uninvested [4][5]. - The company plans to redirect the remaining funds entirely to the new antibacterial peptide drug research project, which will account for 36.33% of the total raised funds [3][4]. Group 3: Project Details - The new project involves the development of antibacterial peptides, which are expected to address the growing issue of antibiotic resistance and have potential applications in treating various infections [6][7]. - The project is anticipated to enhance the company's product offerings and support future business growth [6][9]. Group 4: Approval Process - The change in fundraising usage has been approved by the company's board and requires shareholder approval [9][10]. - The adjustment aligns with regulatory requirements and does not harm shareholder interests [10].

Group 1 - The report is a tracking report by Western Securities Co., Ltd. regarding Hunan Jiutian Pharmaceutical Co., Ltd. for the first half of 2025 [1] - The report includes an overview of the sponsor's work, detailing the review of company information disclosure documents and compliance with regulations [1][2] - The company has not failed to review information disclosure documents, with zero instances of non-compliance noted [1] Group 2 - The company has established a complete set of regulations, including measures to prevent related party transactions and manage raised funds [1] - The company effectively executes relevant regulations, as confirmed by the sponsor [1] - The report indicates that the company attended one shareholder meeting and has conducted two checks on the special fund account for raised funds [1] Group 3 - The report states that there are no significant issues requiring attention from the sponsor [1][2] - The company has not failed to fulfill any commitments, and there are no unresolved issues reported [2]

Group 1 - The company, Western Securities, announced the issuance of its 2024 annual ninth short-term financing bond on November 26, 2024, with an issuance amount of RMB 1 billion [1] - The bond has a coupon rate of 1.93% and a maturity period of 268 days, with the repayment date set for August 22, 2025 [1] - On August 22, 2025, the company will repay the principal and interest of the 2024 annual ninth short-term financing bond, totaling RMB 1,014,170,958.90 [1]

Group 1 - The core point of the news is that Western Securities has been approved to become the major shareholder of Guorong Securities, acquiring 1,151,433,439 shares, which represents 64.5961% of the total shares of Guorong Securities [1][2] - The approval was granted by the China Securities Regulatory Commission, allowing Shaanxi Investment Group Co., Ltd. to become the actual controller of Guorong Securities and its subsidiaries [1] - Eastern Securities, as the bond trustee manager, will closely monitor the issuer's ability to repay the principal and interest of the bonds and other matters that significantly affect the interests of bondholders [2] Group 2 - The report emphasizes the importance of compliance with relevant regulations, including the Company Bond Issuance and Trading Management Measures and the Code of Conduct for Bond Trustees [2] - No additional matters were deemed necessary for explanation by the issuer [1]

债券简称：24 西部 01 债券代码：148699.SZ 债券简称：24 西部 02 债券代码：148753.SZ 债券简称：24 西部 03 债券代码：148865.SZ 债券简称：24 西部 04 债券代码：148924.SZ 债券简称：24 西部 05 债券代码：524008.SZ 债券简称：25 西部 01 债券代码：524106.SZ 债券简称：25 西部 02 债券代码：524164.SZ 债券简称：25 西部 K1 债券代码：524283.SZ 债券简称：25 西部 03 债券代码：524317.SZ 国元证券股份有限公司 关于西部证券股份有限公司 公司债券 2025 年第四次临时受托管理事务报告 发行人：西部证券股份有限公司 住所：陕西省西安市新城区东新街319号8幢10000室 债券受托管理人 住所：安徽省合肥市梅山路18号 签署日期：2025年8月 声明 本报告依据《公司债券发行与交易管理办法》 （以下简称"管理办法"）、 《深 圳证券交易所公司债券上市规则》 《深圳证券交易所公 司债券存续期监管业务指引第 2 号——临时报告》相关信息披露文件以及西部证 券股份有限公司出具的公告等，由西部 ...

东方证券股份有限公司关于西部证券股份有限公司 获准成为国融证券股份有限公司主要股东的临时受托管理事务 报告 发行人于近日披露了《西部证券股份有限公司关于获准成为国融 证券股份有限公司主要股东的公告》，公告重要内容提示简要如下： "西部证券股份有限公司于近日收到国融证券股份有限公司转 发的《关于核准国融证券股份有限公司变更主要股东、实际控制人以 及国融基金管理有限公司、北京首创期货有限责任公司变更实际控制 人的批复》（证监许可〔2025〕1764 号），核准公司成为国融证券 主要股东，核准陕西投资集团有限公司成为国融证券、国融基金管理 有限公司、北京首创期货有限责任公司实际控制人。对西部证券依法 受让国融证券 1,151,433,439 股股份（占公司股份总数 64.5961%）无 异议。" 二、其他发行人认为需要说明的事项 无。 东方证券作为债券受托管理人，根据《公司债券受托管理人执业 行为准则》第十二条、第十八条要求出具本临时受托管理事务报告并 就发行人获准成为国融证券股份有限公司主要股东的临时受托管理 事务报告的事项提醒投资者关注相关风险。东方证券后续将密切关注 发行人对本次债券的本息偿付情况以及其他对债 ...

债券简称：24 西部 01 债券代码：148699.SZ 债券简称：24 西部 02 债券代码：148753.SZ 债券简称：24 西部 03 债券代码：148865.SZ 债券简称：24 西部 04 债券代码：148924.SZ 债券简称：24 西部 05 债券代码：524008.SZ 债券简称：25 西部 01 债券代码：524106.SZ 债券简称：25 西部 02 债券代码：524164.SZ 债券简称：25 西部 K1 债券代码：524283.SZ 债券简称：25 西部 03 债券代码：524317.SZ 发行人：西部证券股份有限公司 住所：陕西省西安市新城区东新街319号8幢10000室 债券受托管理人 住所：安徽省合肥市梅山路18号 国元证券股份有限公司 关于西部证券股份有限公司 公司债券 2025 年第四次临时受托管理事务报告 签署日期：2025年8月 1 声明 本报告依据《公司债券发行与交易管理办法》（以下简称"管理办法"）、《深 圳证券交易所公司债券上市规则》（以下简称"上市规则"）、《深圳证券交易所公 司债券存续期监管业务指引第 2 号——临时报告》相关信息披露文件以及西部证 券股份有限 ...

Core Viewpoint - Western Securities Co., Ltd. issued its ninth short-term financing bond for the year 2024, raising a total of 1 billion RMB with a coupon rate of 1.93% and a maturity period of 268 days [1]. Summary by Relevant Sections - **Bond Issuance Details** - The company issued a short-term financing bond amounting to 1 billion RMB on November 26, 2024 [1]. - The bond has a coupon rate set at 1.93% [1]. - The maturity period for the bond is 268 days, with a repayment date scheduled for August 22, 2025 [1]. - **Financial Implications** - The total interest payable on the bond is approximately 1,014,170,958.90 RMB [1].

| | 证券代码：002673 证券简称：西部证券 | 公告编号：2025-056 | | --- | --- | --- | | | 债券代码：148177 | 债券简称：23西部02 | | | 148339 | 23西部 | | 03 | | | | | 148391 | 23西部 | | 04 | | | | | 148424 | 23西部 | | 05 | | | | | 148699 | 24西部 | | 01 | | | | | 148753 | 24西部 | | 02 | | | | | 148865 | 24西部 | | 03 | | | | | 148924 | 24西部 | | 04 | | | | | 524008 | 24西部05 | | | 524106 | 25西部 | | 01 | | | | | 524164 | 25西部02 | | | 524283 | 25西部K1 | | | 524317 | 25西部03 | 西部证券股份有限公司 2024年度第九期短期融资券兑付完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏 ...